Clinical Trial Update: Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant [Phase 4]

View source ↗

Summary

A Phase 4 trial update evaluating conversion from mycophenolate mofetil to mycophenolate sodium in kidney transplantation; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Mycophenolate mofetil (CellCept) (mycophenolate mofetil)
• Mycophenolate sodium (Myfortic) (mycophenolate sodium)

Snippet

Sponsor: Novartis | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED